Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Moxidectin

FDA-approved product (tablet, oral), marketed as Moxidectin.

Registered studies
25
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Moxidectin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Helminthiasis
  • Onchocerciasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antinematodals
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P02CX03

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae41.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

25registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Moxidectin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Moxidectin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Better Options for Lymphatic Filariasis Treatment

    NCT07159373 · start 2026-03

    Registered record
    Registry ID
    NCT07159373
    Conditions
    Lymphatic Filariasis; Scabies; Strongyloidiasis
    Interventions
    MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole; IDA - Ivermectin + DEC + albendazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2028-06
    Enrolment
    5,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphatic Filariasis; Scabies; Strongyloidiasis
    InterventionMoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole; IDA - Ivermectin + DEC + albendazole
    PhasePhase 3
    Registry statusNot yet recruiting

  • Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases

    NCT07145736 · start 2025-08-04

    Registered record
    Registry ID
    NCT07145736
    Conditions
    Onchocerciasis; Ascaris Lumbricoides Infection; Trichuris Trichiura; Infection; Hookworm Infections; Scabies
    Interventions
    Moxidectin; Ivermectin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-08-04
    Completion
    2029-06-30
    Enrolment
    52,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocerciasis; Ascaris Lumbricoides Infection; Trichuris Trichiura; Infection +2 more
    InterventionMoxidectin; Ivermectin
    PhasePhase 4
    Registry statusRecruiting

  • Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation

    NCT06795165 · start 2025-02-02

    Registered record
    Registry ID
    NCT06795165
    Conditions
    Blepharitis
    Interventions
    Moxidectin 2 MG Oral Tablet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2025-02-02
    Completion
    2025-06-15
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBlepharitis
    InterventionMoxidectin 2 MG Oral Tablet; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC

    NCT06188715 · start 2024-05-14

    Registered record
    Registry ID
    NCT06188715
    Conditions
    Trichuriasis; Ascariasis; Hookworm Infections
    Interventions
    Moxidectin 2 mg Oral Tablet; Albendazole 400 mg Oral Tablet; Placebo Moxidectin; Placebo Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2024-05-14
    Completion
    2024-08-05
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrichuriasis; Ascariasis; Hookworm Infections
    InterventionMoxidectin 2 mg Oral Tablet; Albendazole 400 mg Oral Tablet; Placebo Moxidectin; Placebo Albendazole
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis

    NCT06070116 · start 2024-04-05

    Registered record
    Registry ID
    NCT06070116
    Conditions
    Onchocercal Subcutaneous Nodule; Onchocerciasis; Onchocerciasis, Ocular; Onchocerca Infection; Tropical Disease
    Interventions
    Ivermectin w/ Albendazole; Ivermectin + Diethylcarbamazine + Albendazole; Moxidectin + Albendazole; Moxidectin + Diethylcarbamazine + Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-04-05
    Completion
    2026-09-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocercal Subcutaneous Nodule; Onchocerciasis; Onchocerciasis, Ocular; Onchocerca Infection +1 more
    InterventionIvermectin w/ Albendazole; Ivermectin + Diethylcarbamazine + Albendazole; Moxidectin + Albendazole; Moxidectin + Diethylcarbamazine + Albendazole
    PhasePhase 2
    Registry statusActive not recruiting

  • Efficacy and Safety Study of Moxidectin in Adults With Scabies

    NCT05875441 · start 2023-11-23

    Registered record
    Registry ID
    NCT05875441
    Conditions
    Scabies
    Interventions
    Moxidectin Oral Product; Moxidectin Oral Product; Moxidectin Oral Product; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-11-23
    Completion
    2025-02-11
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionScabies
    InterventionMoxidectin Oral Product; Moxidectin Oral Product; Moxidectin Oral Product; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients

    NCT04049851 · start 2022-04-07

    Registered record
    Registry ID
    NCT04049851
    Conditions
    Onchocerciasis, Ocular; Loiasis
    Interventions
    Moxidectin 2 MG Oral Tablet; Ivermectin 3Mg Tab; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-04-07
    Completion
    2023-07-22
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocerciasis, Ocular; Loiasis
    InterventionMoxidectin 2 MG Oral Tablet; Ivermectin 3Mg Tab; Placebo oral tablet
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis

    NCT04848688 · start 2022-02-05

    Registered record
    Registry ID
    NCT04848688
    Conditions
    Strongyloides Stercoralis Infection
    Interventions
    Moxidectin 2 mg; Ivermectin 3 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-02-05
    Completion
    2022-07-17
    Enrolment
    332

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStrongyloides Stercoralis Infection
    InterventionMoxidectin 2 mg; Ivermectin 3 mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of MOX/ALB Co-administration

    NCT04726969 · start 2021-06-15

    Registered record
    Registry ID
    NCT04726969
    Conditions
    Trichuriasis; Ascariasis; Hookworm Infections
    Interventions
    Moxidectin 2 mg Oral Tablet; Albendazole 400 mg Oral Tablet; Ivermectin 3 mg Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-06-15
    Completion
    2021-09-09
    Enrolment
    255

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrichuriasis; Ascariasis; Hookworm Infections
    InterventionMoxidectin 2 mg Oral Tablet; Albendazole 400 mg Oral Tablet; Ivermectin 3 mg Oral Tablet
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis

    NCT03876262 · start 2021-05-03

    Registered record
    Registry ID
    NCT03876262
    Conditions
    Onchocerciasis
    Interventions
    Moxidectin; Ivermectin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-05-03
    Completion
    2026-01-01
    Enrolment
    323

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocerciasis
    InterventionMoxidectin; Ivermectin
    PhasePhase 3
    Registry statusActive not recruiting

  • Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

    NCT04311671 · start 2021-05-03

    Registered record
    Registry ID
    NCT04311671
    Conditions
    Onchocerciasis
    Interventions
    Moxidectin; Ivermectin; Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-05-03
    Completion
    2024-09-27
    Enrolment
    12,979

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocerciasis
    InterventionMoxidectin; Ivermectin; Albendazole
    PhasePhase 3
    Registry statusCompleted

  • A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years

    NCT03962062 · start 2021-03-29

    Registered record
    Registry ID
    NCT03962062
    Conditions
    Onchocerciasis
    Interventions
    Moxidectin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-29
    Completion
    2022-09-28
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocerciasis
    InterventionMoxidectin
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration

    NCT04700423 · start 2021-03-01

    Registered record
    Registry ID
    NCT04700423
    Conditions
    Trichuriasis; Ascariasis; Hookworm Infections; Helminthes; Infestation, Intestinal
    Interventions
    moxidectin (8 mg) / albendazole (400 mg); ivermectin (200 µg/kg) / albendazole (400 mg); ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]; ivermectin (200 µg/kg); moxidectin (8 mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-03-01
    Completion
    2021-09-22
    Enrolment
    536

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrichuriasis; Ascariasis; Hookworm Infections; Helminthes +1 more
    Interventionmoxidectin (8 mg) / albendazole (400 mg); ivermectin (200 µg/kg) / albendazole (400 mg); ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]; ivermectin (200 µg/kg) +1 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Moxidectin for LF, Cote d'Ivoire (DOLF)

    NCT04410406 · start 2020-08-20

    Registered record
    Registry ID
    NCT04410406
    Conditions
    Lymphatic Filariasis
    Interventions
    Ivermectin; Diethylcarbamazine; Albendazole; Moxidectin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-08-20
    Completion
    2024-10-01
    Enrolment
    164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphatic Filariasis
    InterventionIvermectin; Diethylcarbamazine; Albendazole; Moxidectin
    PhasePhase 3
    Registry statusCompleted

  • Dose-finding Study of Moxidectin for Treatment of Scabies

    NCT03905265 · start 2020-01-13

    Registered record
    Registry ID
    NCT03905265
    Conditions
    Scabies
    Interventions
    Moxidectin Oral Product
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-01-13
    Completion
    2022-02-28
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionScabies
    InterventionMoxidectin Oral Product
    PhasePhase 2
    Registry statusCompleted